Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211300 | 0.83 | MAPK14 (0.53) | TRPV1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL30007391 | 0.83 | MAPK14 (0.53) | TRPV1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2639667 | 0.81 | FEN1 (0.43) | TRPV1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL29604199 | 0.81 | FEN1 (0.43) | TRPV1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL30211282 | 0.80 | SLC2A1 (0.48) | TRPV1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL28479998 | 0.80 | TRPV1 (0.47) | TRPV1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL411041 | 0.80 | SLC2A1 (0.48) | TRPV1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL31306178 | 0.80 | TRPV1 (0.43) | TRPV1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4139478 | 0.80 | SYK (0.47) | TRPV1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL31517665 | 0.79 | MAPK14 (0.53) | TRPV1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240490-B1 | ORGANIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-09-04 | — | — | EP | claimed |
| US-9403836-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2939676-A1 | Organic compounds | Intra-Cellular Therapies, Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20140357606-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2014-12-04 | — | — | US | disclosed |
| US-8829008-B2 | Organic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-09 | — | — | US | disclosed |
| EP-2698160-A2 | Organic compounds | Takeda Pharmaceutical Company Limited (JP) | 2014-02-19 | — | — | EP | disclosed |
| EP-2240490-B1 | ORGANIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8273751-B2 | Organic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120238589-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20100273754-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2010-10-28 | — | — | US | disclosed |
| EP-2240490-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009075784-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273754-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A7 | TRPV1 908/4885GABRG2 998/4885GABRB3 1052/4885 |
| US-20140357606-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A7 | TRPV1 908/4885GABRG2 998/4885GABRB3 1052/4885 |
| US-20120238589-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A7 | TRPV1 908/4885GABRG2 998/4885GABRB3 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.